Clinical Trials Logo

Spinal Muscular Atrophy (SMA) clinical trials

View clinical trials related to Spinal Muscular Atrophy (SMA).

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02876094 Terminated - Clinical trials for Spinal Muscular Atrophy (SMA)

Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy

SMA
Start date: January 29, 2019
Phase: Phase 2
Study type: Interventional

Several factors make the use of celecoxib in human SMA patients appealing including: 1) low-dosing required for potential therapeutic effect (the corresponding dose in humans is much lower than that commonly used in adults and children with; 2) favourable side effect profile of this drug (particularly at the dosing required); 3) the fact that celecoxib crosses the blood brain barrier and 4) demonstration of efficacy in a genetically and pathophysiologically faithful animal mode. The investigators therefore believe that celecoxib is a promising disease modifying therapy for SMA.